Podcasts about Adverse

Irbesartan is an angiotensin II receptor blocker (ARB) used primarily for the management of hypertension and diabetic nephropathy in type 2 diabetes. It selectively inhibits the binding of angiotensin II to the AT1 receptor found in vascular smooth muscle and the adrenal gland. This blockade results in vasodilation, reduced aldosterone secretion, decreased sodium and water retention, and ultimately lower blood pressure. Irbesartan is administered orally, with a typical starting dose of 150 mg once daily, which may be increased to 300 mg depending on the patient's clinical response and tolerability. Adverse effects of irbesartan are generally mild but can include hyperkalemia and dizziness. Hypotension may occur, especially in volume-depleted individuals or those on diuretics. Routine monitoring of renal function and serum potassium is recommended, especially in patients with underlying kidney disease or those taking potassium-sparing agents or supplements. Irbesartan is contraindicated in pregnancy due to the risk of fetal toxicity and should be discontinued as soon as pregnancy is detected.

Entre février 2023 et janvier 2024, Christophe donne des cours de DJ pour une association. Au total, il doit être payé 2.645 €. Problème, l'association n'a réglé qu'une facture de 839 €. Une association déjà connu par la rédaction de l'émission ! Thomas Renard revient sur quelques détails croustillants du dossier... Au micro de Chloé Lacrampe, un membre de l'équipe de "Ça peut vous arriver" revient sur les négociations difficiles et les moments off de ces 2h d'antenne !Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

What are Adverse Religious Experiences (AREs) and spiritual abuse? Aren't they the same thing as religious trauma? Join Andrew and Laura on this week's episode to discuss AREs, spiritual abuse, dynamics of power and control, how this relates to fundamentalism and how all of this…isn't religious trauma? You heard us correctly!  Andrew and Laura discuss all of this AND how these things can result in religious trauma on this episode of Sunday School Dropouts!This podcast is brought to you by the Center for Trauma Resolution and Recovery: an online trauma coaching company whose practitioners are trauma informed and trauma trained to work with individuals, couples and families who have experienced high control religion, cults, and religious trauma. For more information on the support that CTRR provides, for resources–including courses, workshops, and more–head to traumaresolutionandrecovery.com or follow us on Instagram: @traumaresolutionandrecovery The views and opinions expressed by Sunday School Dropouts are those of the hosts and not necessarily reflect the official policy or position of the Center for Trauma Resolution and Recovery. Any of the content provided by our guests, sponsors, authors, or bloggers are their own ideas and opinions.The Sunday School Dropouts podcast is not anti-religion but it is anti -harm, -power and control, -oppression and, -abuse and will speak to the harmful practices and messaging of fundamentalist groups. Follow Andrew on Instagram and TikTok @deconstruct_everything Follow Laura on Instagram and TikTok @drlauraeanderson or on her website: www.drlauraeanderson.com Hosts: Laura Anderson and Andrew KerbsMusic by Benjamin Faye Music @heytherebenji Editing and Production by Kevin Crowe

​Mike Matthews investigates the fascinating news from the week and Mike answers what is happening with people trying to buy a brand new car. Join Mike as he podcasts live from Café Anyway in podCastro Valley with Chely Shoehart, Floyd the Floorman, and John Deer the Engineer. Next show it's Benita, the Disgruntled Fiddle Player, and the Brewmaster.

​Mike Matthews investigates the fascinating news from the week and Mike answers what is happening with people trying to buy a brand new car. Join Mike as he podcasts live from Café Anyway in podCastro Valley with Chely Shoehart, Floyd the Floorman, and John Deer the Engineer. Next show it's Benita, the Disgruntled Fiddle Player, and the Brewmaster.

Hamed Kayello, Product Manager at Georgia-Pacific, joined us to talk about his webinar, “Advanced Design Against Adverse Conditions in a Commercial Roofing System.” Listen in as he chats about some common risk factors when it comes to roof damage, and the benefits of fiber glass gypsum-faced panels. Register for this free webinar

Sports Daily Full Show 7 May 2025

Today's guest is Marie Flanagan, Director of Product Management in Digital Projects and Solutions at IQVIA, who joins us to explore the overlooked intersection of AI and safety workflows in life sciences. As the industry experiences an explosion in the volume and diversity of data—from social media and call centers to audio and video files—Marie outlines the mounting challenges for pharmacovigilance and the opportunities AI is unlocking for healthcare and life sciences leaders. Marie discusses how advancements in voice-to-text transcription and automation are helping safety teams manage massive datasets, pinpoint potential risks, and reallocate human resources toward high-value activities like signaling and benefit-risk management. She also shares insights into where human expertise remains essential, particularly in interpreting complex clinical contexts that AI alone cannot fully capture. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on Emerj's flagship ‘AI in Business' podcast!

Marco Sammon joins Ben and Dan to unpack his latest paper, ‘Index Rebalancing and Stock Market Composition', beginning with how Marco's work (co-written by John Shim) compares to the Nobel Prize-winner Bill Sharpe's paper, ‘Arithmetic of Active Management.' We investigate the missing links in Sharpe's logic before defining “the market” and ascertaining the main objectives of index funds. Then, we dive deeper into the mechanics of Marco's paper, index and market tracking errors, why delayed rebalancing is more beneficial than instant rebalancing, and the role of technology in the modern tracking error obsession. We also assess the passive-active spectrum of index funds in portfolio management and learn how investors should choose their optimal excess return. To end, Marco shares practical applications for improving performance benchmarked against traditional indexes, and The Aftershow is all about bridging the gap between PWL Capital and you, our listeners. Key Points From This Episode:   (0:00:00) Key takeaways from Marco Sammon's latest paper and how it compares to Bill Sharpe's ‘Arithmetic of Active Management.' (0:08:10) Marco describes what's missing from the ‘Arithmetic of Active Management' logic. (0:09:11) Defining ‘the market', the main objective of an index fund, and how index funds track the market. (0:15:57) The mechanics of Marco's paper, ‘Index Rebalancing and Stock Market Composition.' (0:18:38) Factor exposure, index and market tracking errors, and how often index funds trade. (0:26:28) Rebalancing less frequently; why delayed does better than instant rebalancing. (0:31:59) The tech run-up and lazy rebalancing, and the modern tracking error obsession.  (0:36:51) Assessing the passive-active spectrum of index funds in portfolio management. (0:41:02) Exploring how investors should decide on their optimal excess return.  (0:45:14) How the rising index fund ownership of stocks impacts the implicit cost of indexing (0:46:58) Practical ways to improve performance benchmarked against traditional indexes. (0:52:30) The Aftershow: Canadian finances, more airtime for Cameron, and PWL – OneDigital.    Links From Today's Episode: Meet with PWL Capital — https://calendly.com/d/3vm-t2j-h3p Rational Reminder on iTunes — https://itunes.apple.com/ca/podcast/the-rational-reminder-podcast/id1426530582. Rational Reminder Website — https://rationalreminder.ca/  Rational Reminder on Instagram — https://www.instagram.com/rationalreminder/ Rational Reminder on X — https://x.com/RationalRemindRational Reminder on TikTok — www.tiktok.com/@rationalreminder Rational Reminder on YouTube — https://www.youtube.com/channel/ Rational Reminder Email — info@rationalreminder.caBenjamin Felix — https://pwlcapital.com/our-team/ Benjamin on X — https://x.com/benjaminwfelix Benjamin on LinkedIn — https://www.linkedin.com/in/benjaminwfelix/ Dan Bortolotti on LinkedIn — https://www.linkedin.com/in/dan-bortolotti-8a482310/ Episode 322: Prof. Marco Sammon: How are Passive Investors Affecting the Stock Market? — https://rationalreminder.ca/podcast/322 Episode 200: Prof. Eugene Fama — https://rationalreminder.ca/podcast/200  Episode 268: Itzhak Ben-David: ETFs, Investor Behavior, and Hedge Fund Fees — https://rationalreminder.ca/podcast/268  Episode 112: Michael Kitces: Retirement Research and the Business of Financial Advice — https://rationalreminder.ca/podcast/112  Marco Sammon — https://marcosammon.com/  Marco Sammon on LinkedIn — https://www.linkedin.com/in/marco-sammon-b3b81456/  Marco Sammon on X — https://x.com/mcsammon19  Marco Sammon | Harvard Business School — https://www.hbs.edu/faculty/Pages/profile.aspx?facId=1326895  Marco Sammon Email — mcsammon@gmail.com  John Shim on LinkedIn — https://www.linkedin.com/in/john-shim-2931271b/  Vanguard — https://global.vanguard.com/  Sheridan Titman on LinkedIn — https://www.linkedin.com/in/sheridan-titman-226b0811/  Alex Chinko — https://alexchinco.com/  Erik Stafford | Harvard Business School — https://www.hbs.edu/faculty/Pages/profile.aspx?facId=6625  Itzhak (Zahi) Ben-David on LinkedIn — https://www.linkedin.com/in/ibendavi/  Bill Ackman on X — https://x.com/billackman   ‘Millennium Loses $900 Million on Strategy Roiled by Market Chaos' — https://www.bloomberg.com/news/articles/2025-03-08/millennium-loses-900-million-on-strategy-roiled-by-market-chaos   Bogleheads — https://www.bogleheads.org/   The Money Scope Podcast Episode 8: Canadian Investment Accounts — https://moneyscope.ca/2024/03/01/episode-8-canadian-investment-accounts/  The Wealthy Barber Podcast — https://thewealthybarber.com/podcast/   Financial Advisor Success Podcast — https://www.kitces.com/blog/category/21-financial-advisor-success-podcast/  Financial Advisor Success Podcast Episode 433: When You 10X Your Advisory Firm To Over $20M Of Revenue…And Want To 10X Again, With Cameron Passmore — https://www.kitces.com/blog/cameron-passmore-pwl-capital-10x-revenue-growth-advisory-firm/   OneDigital — https://www.onedigital.com/  The Longview Podcast: Ben Felix   Papers From Today's Episode:    ‘The Arithmetic of Active Management' — https://www.jstor.org/stable/4479386    ‘Index Rebalancing and Stock Market Composition: Do Index Funds Incur Adverse Selection Costs?' — https://papers.ssrn.com/sol3/papers.cfm?abstract_id=5080459     ‘Luck versus Skill in the Cross-Section of Mutual Fund Returns' — https://papers.ssrn.com/sol3/papers.cfm?abstract_id=1356021    ‘The Passive-Ownership Share Is Double What You Think It Is' — https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4188052    ‘Long-Term Returns on the Original S&P 500 Companies' — https://www.researchgate.net/publication/247884354_Long-Term_Returns_on_the_Original_SP_500_Companies     ‘The Price of Immediacy' — https://papers.ssrn.com/sol3/papers.cfm?abstract_id=1001762   ‘Competition for Attention in the ETF Space' — https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3765063    ‘Passive in Name Only: Delegated Management and “Index” Investing' — https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3244991      Jeremy Stein — “Unanchored” Strategy

Video Version Only on HCPLive! In this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, break down new Phase 3 data from the ESSENCE trial examining semaglutide 2.4 mg (Wegovy) for metabolic dysfunction-associated steatohepatitis (MASH) with stage 2 or 3 fibrosis. With results published in The New England Journal of Medicine, hosts are joined by first author Arun J. Sanyal, MD, director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University, to discuss key takeaways from part 1 of the ESSENCE trial, semaglutide's impact on liver outcomes and weight loss, and what the data could mean for the future of MASH treatment. ESSENCE Once-weekly semaglutide 2.4 mg significantly improved liver outcomes in patients with metabolic dysfunction–associated steatohepatitis (MASH) and stage 2 or 3 fibrosis, according to findings from the ESSENCE trial. In part 1 of the ongoing, double-blind, placebo-controlled trial, 800 patients were evaluated at 72 weeks for two primary endpoints: resolution of steatohepatitis without worsening fibrosis, and fibrosis improvement without worsening steatohepatitis. Spanning 253 sites in 37 countries, the full trial enrolled 1197 biopsy-confirmed patients between May 2021 and April 2023. At the interim analysis, semaglutide achieved both primary endpoints. Resolution of steatohepatitis without fibrosis worsening occurred in 62.9% of patients receiving semaglutide compared with 34.3% in the placebo group (difference, 28.7%; 95% CI, 21.1–36.2; P

Watch every episode ad-free & uncensored on Patreon: https://patreon.com/dannyjones Rick Strassman is best known for pioneering DMT research in humans and proposing that DMT could be a biological gateway to mystical or alternate realities. Currently, Dr. Strassman serves as a Clinical Associate Professor of Psychiatry at the University of New Mexico School of Medicine. His new book, "My Altered States: A Doctor's Extraordinary Account of Trauma, Psychedelics, and Spiritual Growth," is available now. SPONSORS http://morning.ver.so/danny - Use code DANNY for 15% off your first order. https://hims.com/danny - Start your FREE online visit today. https://whiterabbitenergy.com/?ref=DJP - Use code DJP for 20% off EPISODE LINKS https://x.com/rick_strassman https://www.rickstrassman.com FOLLOW DANNY JONES https://www.instagram.com/dannyjones https://twitter.com/jonesdanny OUTLINE 00:00 - Adverse effects of DMT 06:54 - Is DMT the source of human consciousness? 10:25 - Extended state DMT experiments 20:19 - DMT reveals a universal religion 29:08 - Psychedelic religion of mystical consciousness 35:10 - What Danny saw during DMT experiment 37:54 - Terrifying experience on 5-MeO DMT 41:39 - Melatonin & the pineal gland 52:43 - When DMT stops working 57:38 - DMT & NDE's 01:02:45 - Telepathic experiences on psychedelics 01:12:53 - Prophets of the bible 01:18:34 - The first anti-christ 01:31:42 - Drugs in antiquity 01:37:24 - CIA-funded LSD clinics w/ Charles Manson 01:40:13 - Rick's friendship with Joe Rogan 01:45:42 - Did ergot & psychedelics create religion? 01:53:12 - Government research on psychedelic soldiers 02:03:01 - Amphetamines & adderall 02:14:00 - Next species of humans will have telepathy 02:19:39 - John Mack's alien research vs. psychedelics 02:26:53 - Remembering previous lives 02:29:20 - Translating the book of Genesis 02:34:06 - DARPA research on buddhism Learn more about your ad choices. Visit podcastchoices.com/adchoices

Nearly forty medical drugs have been recalled by the Food and Drug Administrationover fears of faulty manufacturing. All of the medical drugs in question were produced byGlenmark Pharmaceuticals Inc at its factory in India and were initially recalled on March13. The FDA gave the recall a Class II risk level on April 8 th . If you take any medical drugs,over the counter or prescription standby for FDA warnings information.Special Guest – Larry Logsdon ‘How to Safely & Effectively Relieve AcidRefux/Heartburn'

In this podcast, Dr. Valentin Fuster discusses a study on pre-pregnancy obesity and its long-term effects on pregnancy outcomes and cardiovascular health later in life. The research highlights how pre-pregnancy obesity and overweight increase the risk of gestational diabetes, hypertension, and future cardiovascular disease, underscoring the need for early weight management and more research on treatments like GLP-1 receptor agonists.

This episode challenges the dental industry's casual approach to gingivitis and reframes bleeding gums as a severe systemic health warning that demands attention! Melissa and Tabitha reveal why making gingivitis identification compelling to patients is crucial for oral and overall health outcomes. Link to Meissa's Post mentioned in the episode:  https://www.instagram.com/reel/DG0LnVGsrnT/?utm_source=ig_web_copy_link&igsh=MzRlODBiNWFlZA== Key Topics Covered

Show Notes: Cara Natterson moved to New York City where she worked for a drug rehabilitation center, and later moved to Baltimore, where she studied at Johns Hopkins Medical School. She eventually returned to L.A. and practiced pediatrics there. Her writing career began at the age of 31 when a co-worker asked her to read his manuscript, which inspired her to write her own book about raising kids. The Body Book Series and Less Awkward Company In 2008, Cara decided to leave clinical medicine and become a full-time writer. In 2011, after speaking at Mattel, she was signed on to write for the Body Book series from American Girl, which has since sold millions of copies. Cara then started touring the country, focusing on puberty education. During this time, she discovered that there was nothing else available for kids whose bodies, brains, feelings, and friends were changing. She launched her own business, Less Awkward, a company that created direct-to-consumer products designed for comfort and health like bras and socks. Cara has since expanded the company to focus on content across social media, podcasting, newsletter, and school curriculum. Health and Sex Education Curriculum In the past year, she has rolled out two platforms: a health and sex education curriculum for schools, which is already implemented in three states, and a membership for parents and trusted adults. Cara talks about the importance of understanding and discussing puberty in young people. She highlights the slower pace of puberty, with girls entering puberty at an average age of 8-9, and boys at an average age of 9-10. She emphasizes the importance of discussing the first signs of puberty, such as breast budding or testicular growth. She also highlights the importance of discussing the issue of first porn exposure, which is a significant concern for parents, family members, coaches, mentors, healthcare providers, and educators. She emphasizes the need to educate children about free porn, which is generally violent and aggressive, and calls for a less awkward approach to discussing this topic. By engaging in conversations about this topic, adults can help their children navigate the challenges of puberty and promote healthier lifestyles. Launching a Direct-to-Consumer Product Cara talks about the shift from a pediatrician to writer to entrepreneur. She initially went to medical school but, although she found it interesting, she also realized that she was more of a creative type. However, her background combined with her creative mind led to the drive to develop comfortable and healthy products. After a chat with a friend about bras, she was convinced that there was a need for comfortable bras for young girls. The two women partnered with a sewer who made a comfortable and healthy bra for their daughters, and later pulled together a team that developed the product over many years. They patented the product and launched the company during the COVID-19 pandemic. It was initially launched as a mask company, focusing on distribution and production channels instead of bras to supply the then current demand. Six months later they launched their bra products. She talks about the journey from design and development to launching the product and what she learned along the way. Cara's business ethos has always been to do well and to do good at the same time, and she has found this to be a recipe for success. The This Is So Awkward Podcast The conversation turns to Cara's podcast which she started with her partner, Vanessa Kroll Bennett. The podcast addresses the confusion about the length of puberty. It features background episodes and guest appearances with experts from various fields. In October 2023, they published a book called This Is So Awkward: Modern Puberty Explained, which explores the changes in puberty and how to talk about them, and it includes essays by kids about their experiences with acne, first periods, and heartbreaks. The podcast has expanded along with content on Instagram and TikTok. All of this content is also available on the website LessAwkward.com. They also have a school-based health and sex education curriculum called That Health Class. Navigating Today's Cultural Complexities Cara emphasizes the importance of pediatricians in understanding and managing the changes in puberty. She explains that kids and their adults are overwhelmed by the complexity of the world and the increased access to a wide and diverse range of information. Pediatricians often lack the time or bandwidth to provide anticipatory guidance for children, an especially big issue given the mental health crisis among children. Cara mentions that pediatricians often turn to the LessAwkward website where they have trained an AI bot on their content. Pediatricians are starting to use it as a healthcare solution when they don't have the time to answer questions but their patients want to be able to anticipate what's coming. The bot is reliable, gated, and trained on good data, making it engaging and entertaining. The levity and warmth of the content make it a valuable tool for pediatricians to recommend. Factors that Contribute to Early Puberty The American Girl Body Book series launched just after a 1997 study showed that girls were entering puberty earlier. It stated that the average age has shifted from 11 to 10, and a follow-up study in 2010 found it to be between eight and nine. The reason for this change is under investigation, but it is believed to be due to a number of factors, including stress, adverse childhood experiences, and antibiotics. Stress causes cortisol surges, which can either trigger the release of hormones like LH and FSH, or cause sex hormones to surge. Adverse childhood experiences, such as witnessing trauma or drug abuse, can increase the risk of entering puberty early. Evolutionary theory suggests that the human body is meant to reproduce before life ends, and so it makes sense that the general stress response might drive earlier development. She mentions Louise Greenspan, a woman who has been researching puberty for decades, has written a book called The New Puberty which further explores this topic. The Male Side of the Story Cara's parenting podcast has a diverse audience, with nearly 20% male listenership. She shares her experiences with male listeners and the challenges they face in connecting with their children. She wrote Decoding Boys, and states, with a degree of jocularity, that there is no data on the connection between testosterone and silence, but it is common among males, especially in their tween years. She shares personal strategies to help connect with tween or teen boys, as they do want to talk and share their thoughts with trusted adults. In the book, Cara shares strategies she has used, and in this conversation, she shares a personal experience on how she encouraged her son to talk to her.  Influential Harvard Courses and Professors Cara's career highlights her interest in sociology and biological anthropology, which she combined at Harvard. She wrote a junior paper about female genital mutilation in Africa and a thesis about HIV prevention in teenagers in Boston suburbs. She had a vivid memory of her thesis advisor, Irven DeVore, who was an interesting thinker and helped her fit her thesis idea into the curriculum. Timestamps: 02:12: Transition to Entrepreneurship  05:46: Insights on Puberty and Parenting 09:20: Launching Less Awkward  15:42: Content Creation and Engagement  29:05: Raising Boys and Communication Strategies  35:15: Daily Routine and Collaboration  37:19: Impact of Social Media and Content Creation  39:14: Influence of Harvard Education  Links: Website: https://lessawkward.com/ Podcast: https://lessawkward.com/podcast-this-is-so-awkward-2/ Instagram: less.awkward TikTok: less.awkward Cara's Instagram: caranatterson Featured Non-profit: The featured non-profit of this episode of The 92 Report is recommended by Chris Hull who reports: “Hi. I'm Chris Hull from Harvard's fabulous class of 1992. The featured nonprofit of this episode of The 92 report is The Funds for American Studies. TFAs is an educational nonprofit that develops courageous leaders by providing students who otherwise wouldn't get a chance to come to DC to learn about how to make a difference. I've been honored to have worked with TFAs for more than three decades, since they've allowed me to study at Georgetown. At the same time, I did an internship in Washington, which helped transform my life as it has for so many others over the last half century that it's existed, who otherwise couldn't possibly afford to do such a thing. You can learn more about their work@tfas.org.” To learn more about their work, visit: work@tfas.org

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/CaseConsultAdverseEffectMonitoringManagementandMitigationDuringTargetedTherapyforBRAFMutantmCRc/33134/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, the management of treatment-related adverse events.

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/ProactiveAdverseEffectManagementinmCRCImprovingTolerabilitytoOptimizePatientOutcomes/32945/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, the management of treatment-related adverse events.

Welcome to episode 118 of Growers Daily! We cover:   the fascinating world of shade cloth colors, maximizing vermicompost and what to do about those overwintered carrots. We are a Non-Profit! 

Depending on who you talk to, labor reform is desperately needed in agriculture, with costs soaring, pricing out more and more farmers every day.

Depending on who you talk to, labor reform is desperately needed in agriculture, with costs soaring, pricing out more and more farmers every day.

CME credits: 0.50 Valid until: 26-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/antibody-drug-conjugates-in-bladder-cancer-guideline-updates-and-adverse-event-management/29174/ New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide management strategies for common AEs seen with newer immunotherapy.=

Host: Elizabeth R. Plimack, MD, MS, FASCO Guest: Shilpa Gupta, MD New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide management strategies for common AEs seen with newer immunotherapy.

Send us a textIn this episode, Dr. Chastain and Ginger will help you understand:Assessment of cattle welfareInjuries from poor handling facilitiesHandling methods adverse to the health and safety of cattleLink to show notes: BetterAnimalHandling.com

Adverse possession allows a person to claim ownership of land that they have occupied for more than ten years without the owner's permission. In this decision, the Supreme Court clarifies the law surrounding how and when these claims should be made. https://uklawweekly.substack.com/subscribe Music from bensound.com

Former Fox News and NBC News commentator and current Sirus XM host of The Megyn Kelly Show recently disclosed she is suffering from a Covid 19 vaccine injury. Megyn has claimed she was injured by the Pfizer Covid vaccine/shot. On the latest episode of her podcast, the conservative commentator said she developed an ‘unspecified autoimmune condition' after getting two Covid shots and a booster. Dr. Bob Martin – answers listeners health questions on The Dr. Bob Martin Show – Caller Hotline # 800-606-8822

Drug interactions can cause more complex side effects than the side effects of a single drug, and can even contribute to dementia. Join me as I interview Hal Cranmer, owner of several assisted living homes, and Dr. Roshani Sanghani, board-certified endocrinologist, to discuss the side effects of multiple medications. Assisted Living Home: https://aparadiseforparents.com/Epocrates:https://www.epocrates.com/Taking the following drugs for an extended period of time may potentially increase your risk for dementia. 1. Drugs that block acetylcholineThis includes Benadryl, certain drugs for depression, and drugs that treat overactive bladder. 2. BenzodiazepineDrugs such as Valium and Xanax treat anxiety, insomnia, and seizures, affecting the central nervous system and brain.3. PPIsProton pump inhibitors, such as Prilosec and Nexium, that treat indigestion and heartburn may increase the risk of cognitive decline.4. Opioids Morphine, oxycodone, and other opioids that sedate the brain significantly affect cognitive function and may lead to dementia. Hal Cranmer owns several assisted living homes and sees first-hand the consequences of giving someone several drugs at once. Many residents in assisted living homes are on 20 to 30 medications. In Hal's facilities, he focuses on providing his residents with a healthy diet and eliminating sugar and ultra-processed foods. Many of Hal's residents have been able to get off their medication. Multiple medications often involve multiple doctors with multiple viewpoints. Each doctor focuses only on specific parts and functions of the body rather than the body as a whole. Adverse drug reactions are unexpected side effects directly caused by drugs. Around 90% are underreported. Adverse drug reactions are responsible for 10% of all hospital visits and are the 4th leading cause of death. Dr. Roshani Sanghani, a board-certified endocrinologist, uses epocrates.com to help keep track of drug interactions. She points out the problem of specialists focusing on and prescribing treatment for one body part and not considering the patients' other medications. The biggest contributor to chronic disease is diet. Medications are often prescribed to treat the symptoms caused by consuming ultra-processed foods. A healthy diet can turn this cycle around.

DEAR PAO: Concept of third party adverse possessor | Mar. 14, 2025Visit our website at https://www.manilatimes.netFollow us:Facebook - https://tmt.ph/facebookInstagram - https://tmt.ph/instagramTwitter - https://tmt.ph/twitterDailyMotion - https://tmt.ph/dailymotionSubscribe to our Digital Edition - https://tmt.ph/digitalSign up to our newsletters: https://tmt.ph/newslettersCheck out our Podcasts:Spotify - https://tmt.ph/spotifyApple Podcasts - https://tmt.ph/applepodcastsAmazon Music - https://tmt.ph/amazonmusicDeezer: https://tmt.ph/deezerStitcher: https://tmt.ph/stitcherTune In: https://tmt.ph/tunein#TheManilaTimesVisit our website at https://www.manilatimes.netFollow us:Facebook - https://tmt.ph/facebookInstagram - https://tmt.ph/instagramTwitter - https://tmt.ph/twitterDailyMotion - https://tmt.ph/dailymotionSubscribe to our Digital Edition - https://tmt.ph/digitalSign up to our newsletters: https://tmt.ph/newslettersCheck out our Podcasts:Spotify - https://tmt.ph/spotifyApple Podcasts - https://tmt.ph/applepodcastsAmazon Music - https://tmt.ph/amazonmusicDeezer: https://tmt.ph/deezerStitcher: https://tmt.ph/stitcherTune In: https://tmt.ph/tunein#TheManilaTimes Hosted on Acast. See acast.com/privacy for more information.

In this engaging episode of Shark Theory, host Baylor Barbee turns an impromptu challenge into a profound life lesson using a seemingly simple birthday cake as a metaphor. Challenged to find inspiration from a cake, Baylor explores the parallels between cake-making and personal growth, emphasizing the importance of the "oven" moments in life where ingredients—often appearing unpalatable on their own—combine under pressure to create something beautiful. He eloquently connects this analogy to the importance of recognizing and valuing one's unique life ingredients, or skills, highlighting the necessity of adversity as a refining force that ultimately leads to success. Baylor delves into the transformative power of adversity, encouraging listeners to embrace challenges as essential steps to unlocking their full potential. He stresses that facing setbacks isn't about giving up but recognizing these moments as a crucial part of the refining process that life demands. With a vivid tie to his own experiences, including how the COVID-19 pandemic tested the principles outlined in his book "Opportunity Engineer," Baylor reiterates the opportunity inherent in every obstacle. This episode is a call to action for listeners to inventory their skills, embrace adversity, and actively shape their lives into a celebrated masterpiece. Key Takeaways: The metaphor of cake-making illustrates personal growth, with each ingredient representing the skills and experiences that shape our lives. Adverse situations, much like the oven for a cake, serve as a necessary component for refining and realizing our true potential. Identifying personal skills and taking inventory of one's life is crucial to understanding what one can offer to the world. Viewing adversity through a positive lens can turn setbacks into opportunities, reinforcing resilience and capability. The importance of proactive engagement in life's "cooking process," aligning one's passions and skills to bring something meaningful into the world. Notable Quotes: "Everybody wants the finished product, but nobody realizes the ingredients that lead up to it and what the cake has to go through." "The fire in life is the adversities we face. It's the setbacks, it's the obstacles." "When somebody puts you to the fire, are they finding out that you're real? Or are they finding out that you're a fraud?" "If I can put my head down and work through this adversity, then I can see what I'm truly made of." "What are you cooking? What are you putting into the world?"

0:00 Intro2:25 Adverse Selection Deep Dive 40:35 Betting News1:14:35 How to Tell your Friends & Family You are a Pro Degen1:27:11 Live EV Betting v. Live Arbing1:34:25 Dealing with Downswings1:52:37 Why GP NO MORE PICKS?!?Welcome to The Risk Takers Podcast, hosted by professional sports bettor John Shilling (GoldenPants13) and SportsProjections. This podcast is the best betting education available - PERIOD. And it's free - please share and subscribe if you like it.My website: https://www.goldenpants.com/ Follow SportsProjections on Twitter: https://x.com/Sports__ProjWant to work with my betting group?: john@goldenpants.comWant 100s of +EV picks a day?: https://www.goldenpants.com/gp-picks

Dr. Mellar Davis discusses the joint guideline from MASCC, ASCO, AAHPM, HPNA, and NICSO on opioid conversion in adults with cancer. He reviews the limited evidence, and the formal consensus process used to develop the guideline. He shares the key recommendations on pre-conversion assessment, how opioid conversion should be conducted, including opioid conversion ratios, and post-conversion assessment. We touch on gaps and questions in the field and the impact of these new recommendations.  Read the full guideline, “Opioid Conversion in Adults with Cancer: MASCC-ASCO-AAHPM-HPNA-NICSO Guideline” at www.asco.org/supportive-care-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/supportive-care-guidelines. Read the full text of the guideline in the Supportive Care in Cancer, https://link.springer.com/article/10.1007/s00520-025-09286-z   Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows, including this one at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Mellar Davis from Geisinger Medical Center, lead author on “Opioid Conversion in Adults with Cancer: Multinational Association of Supportive Care and Cancer, American Society of Clinical Oncology, American Academy of Hospice and Palliative Medicine, Hospice and Palliative Nurses Association, Network Italiano Cure di Supporto and Oncologia Guideline.” Thank you for being here today, Dr. Davis. Dr. Mellar Davis: Thank you. I'm glad to be here. Brittany Harvey Before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Davis, who has joined us here today, are available online with the publication of the guideline, which is linked in our show notes. So then, to dive into the content here, Dr. Davis, can you provide an overview of both the scope and purpose of this guideline on opioid conversion in people with cancer? Dr. Mellar Davis: This is an important topic in management of cancer pain and this topic came up as a result of a survey that MASCC had done, which involved 370 physicians in 53 countries. They were queried about how they change or convert one opioid to another, which is a common practice, and we found that there was quite a divergence in opioid conversion ratios. To step back a little bit, about two thirds of patients with advanced cancer have moderate to severe pain and most of the time they're managed by opioids. But about 20% or 40% require a switch either because they have an adverse reaction to it or they don't respond to it, or the combination of both. Rarely, it may be that they need a route change, perhaps because they have nausea or vomiting. So, the opioid conversion works basically because of the complexity of the new opioid receptor which has at least four exons to it as a result of that non-cross tolerance between opioids. As a result of the survey, we convened a group of specialists, 14 international specialists, to look to see if we could develop an international guideline. And we did a systematic review which involved viewing 21,000 abstracts and we came up with 140 randomized trials and 68 non-randomized trials. And after reviewing the data, we found that the data was really not strong enough to provide a guideline. As a result, ASCO, MASCC, the AAHPM, the HPNA and the Italian Group formed a supportive network that allowed us then to do a Delphi guideline based upon ASCO modified criteria for doing Delphi guidelines. And so we then involved 27 additional international experts informing the guideline to it. And this guideline is then the result of the Delphi process. It consists basically of a pre-conversion ratio recommendations, conversion ratios, which is actually a major contribution of this guideline, and then what to do after converting someone to another opioid. Our target audience was not only oncologists, but also we wanted to target nurses, pharmacists, hospitalists, primary care physicians, patients and caregivers. Brittany Harvey: I appreciate that background information, particularly on the evidence that is underpinning this and the lack of quality of evidence there, which really transformed this into a formal consensus guideline. We're glad to have all of these organizations coming together to collaborate on this guideline. So then next I'd like to review the key recommendations. So starting with, what is recommended for pre-conversion assessment? Dr. Mellar Davis: In regards to pre-conversion, physicians and clinicians need to be aware of pain phenotypes. That is, there are pains that are more opioid refractory than others, such as neuropathic pain, hence, they may be more resistant to the opioid that you're converting to. One needs to be aware of the fact that patients may not be compliant, they're either afraid of opioids not taking what was prescribed, so it's important to query patients about whether they are taking their opioid as prescribed. Occasionally, there are patients who will divert their medication for various reasons. Pain may be poorly controlled also because of dosing strategies that are poorly conceived, in other words, giving only ‘as needed' opioids for continuous cancer pain. And there are rare circumstances where an opioid actually induces pain and simply reducing the opioid actually may improve the pain. The other issue may be cancer progression. So that poorly controlled pain or rapidly increasing pain may actually be a result of progressive cancer and changing treatment obviously will be important. And you need to assess the pain severity, the quality of the pain, the radiating localizing effects, which does require not only a physical exam but also radiographic examinations. But the other thing that's very important in opioid conversions are pain scales with function. A significant number of patients don't quite understand a numerical scale which we commonly use: 0 to 10, with 10 being severe pain and 0 being no pain. They may in fact focus more on function rather than on pain severity or pain interference with daily activities or roles. Sometimes patients will say, “Oh, my pain is manageable,” or “It's tolerable,” rather than using a numerical scale. Choices of opioids may be based on cost, drug-drug interactions, organ function, personal history or substance use disorder so that one will want to choose an opioid that's safe when converting from one to another. And obviously social support and having caregivers present and understanding the strategy in managing pain will be important. Brittany Harvey: Thank you, Dr. Davis, for reviewing those pre-conversion assessment considerations and particularly the challenges around some of those. So, following this pre-conversion assessment, what are the recommendations on how opioid conversion should be conducted? Dr. Mellar Davis: Opioid conversions are basically the safe dose. People have used the term ‘equianalgesia', but the panel and the consensus group felt that that would be inappropriate. So a conversion ratio is the dose at which the majority of patients will not experience withdrawal or adverse effect. It would be the safe dose. Thereafter, the dose will need to be adjusted. So, in converting, that's only the first step in managing pain, the doses need to be adjusted to the individual thereafter. There are a significant number of conversions that are done indirectly, that is that there has not been a study that has looked at a direct conversion from one opioid to another in which one needs to convert through another opioid. We call that a ‘morphine equivalent daily dose'. So, most of the time a third opioid is used in the conversion. It allows you then to convert when there hasn't been a direct study that has looked at conversion between those two opioids, but it is less accurate and so one has to be a little bit more careful when using morphine daily equivalents. We found, and I think this is the major advantage to the guideline, is that commonly used opioids - oxycodone, morphine, hydromorphone - we did establish conversion ratios to which we found in the MASCC guideline they were widely divergent and hope that actually, internationally, they will be adopted. We also found some conversion ratios for second-line opioids. However, we felt also that an opioid like methadone, which has a unique pharmacology, should be left to experts and that experts should know at least several ways of converting from morphine usually to methadone. There is what appears to be a dose-related increased potency of methadone relative to morphine, which makes it more difficult, particularly at higher doses, to have an accurate conversion ratio. Most patients will have transient flares of pain. We came up with two suggestions. One is using a 10 or 15% of the around-the-clock dose for the breakthrough dose, but we also realized that there was a poor correlation between the around-the-clock dose and the dose used for transient flares of pain. And so the breakthrough dose really needs to be adjusted to the individual responses. There was also a mention of buprenorphine. One of the unique things about buprenorphine is that if you go from high doses of a drug like morphine to buprenorphine in a stop-start dosing strategy, you can precipitate withdrawal. And so one has to be careful and have some experience in using buprenorphine, which can be an effective analgesic. Brittany Harvey: Yes, I think that the conversion ratios that you mentioned that are in Table 3 in the full guideline are a really useful tool for clinicians in practice. And I appreciate the time that the panel and the additional consensus panel went through to develop these. I think it's also really key what you mentioned about these not being equianalgesic doses and the difficulties in some of these conversions and when people need to really look to specialists in the field. So then, following opioid conversion, what assessments are recommended post-conversion? Dr. Mellar Davis: Post-conversion, probably the cardinal recommendation is close observation for response and for toxicity. And I think that probably summarizes the important parts of post-conversion follow up. So assessment should be done 24-48 hours after conversion and patients followed closely. Assessment scales should include patient personalized goals. Now, it used to be in the past that we had this hard stop about a response being below 4 on a 0 to 10 scale, but each patient has their own personal goals. So they gauge the pain severity and their function based upon response. So a patient may function very well at “a severity of 5” and feel that that is their personal goal. So I think the other thing is to make sure that your assessment is just not rote, but it's based upon what patients really want to achieve with the opioid conversion. The average number of doses per day should be assessed in the around-the-clock dose so those should be followed closely. Adverse effects can occur and sometimes can be subtle. In other words, a mild withdrawal may produce fatigue, irritability, insomnia and depression. And clinicians may not pick up on the fact that they may be actually a bit under what patients have or they're experiencing withdrawal syndrome. It's important to look for other symptoms which may be subtle but indicating, for instance, neurotoxicity from an opioid. For instance, visual hallucinations may not be volunteered by patients. They may transiently see things but either don't associate with the opioid or are afraid to mention them. So I think it's important to directly query them, for instance, about visual hallucinations or about nightmares at night. Nausea can occur. It may be temporary, mild, and doesn't necessarily mean that one needs to stop the second opioid. It may actually resolve in several days and can be treated symptomatically. Pruritus can occur and can be significant. So close observation for the purposes of close adjustments are also necessary. As we mentioned, you want to start them on an around-the-clock of breakthrough dose, but then assess to see what their response is and if it's suboptimal then you'll need to adjust the doses based both upon the around-the-clock and the breakthrough dose or the dose that's used for breakthrough pain. Also looking at how patients are functioning, because remember that patients frequently look at pain in terms of function or interference with their roles during the day. So, if patients are able to do more things, that may, in fact, be the goal. Brittany Harvey: Thank you for reviewing all of these recommendations across pre-conversion assessment, how opioid conversion should be conducted, including conversion ratios, and what assessments are recommended after opioid conversion. I think it's really important to be watching for these adverse events and assessing for response and keeping in mind patient goals. So, along those lines, how will these guideline recommendations impact both clinicians and people with cancer? And what are the outstanding questions we're thinking about regarding opioid conversion? Dr. Mellar Davis: I think it's important to have a basic knowledge of opioid pharmacology. There's, for instance, drugs that are safer in liver disease, such as morphine, hydromorphone, which are glucuronidated. And there are opioids that are safer in renal failure, such as methadone and buprenorphine, which aren't dependent upon renal clearance. I think knowing drug-drug interactions are important to know. And sometimes, for instance, there may be multiple prescribers for a patient. The family physician's prescribing a certain medication and the oncologist is another, so being aware of what patients are on, and particularly over-the-counter medications which may influence opioid pharmacokinetics. So complementary medications, for instance, being aware of cannabis, if patients are using cannabis or other things, I think, are important in this. There are large gaps and questions and that's the last part of the guideline that we approach or that we mentioned that I think are important to know. And one is there may be ethnic differences in population in regards to clearance or cytochrome frequencies within communities or countries, which may actually alter the conversion ratios. This has not been explored to a great extent. There's opioid stigmata. So we are in the middle of an opioid crisis and so people have a great fear of addiction and they may not take an opioid for that reason, or they may have a relative who's been addicted or had a poor experience. And this may be particularly true for methadone and buprenorphine, which are excellent analgesics and are increasingly being used but may in fact have the stigmata. There are health inequalities that occur related to minority groups that may in fact not get the full benefit of opioid conversions due to access to opioids or to medical care. Age, for instance, will cause perhaps differences in responses to opioids and may in fact affect conversion ratios. And this may be particularly true for methadone, which we have not really explored to a great extent. And finally, the disease itself may influence the clearance or absorption of an opioid. So for a sick patient, the opioid conversion ratio may be distinctly different than in a healthy individual. This is particularly seen with transdermal fentanyl, which is less well absorbed in a cachectic patient, but once given IV or intravenously has a much longer half life due to alterations in the cytochrome that clears it. And so conversion ratios have frequently been reported in relatively healthy individuals with good organ function and not that frequently in older patient populations. So just remember that the conversion ratios may be different in those particular populations. Brittany Harvey: Yes. So I think a lot of these are very important things to consider and that managing cancer pain is key to quality of life for a lot of patients and it's important to consider these patient factors while offering opioid conversion. I want to thank you so much for your work to review the existing literature here, develop these consensus-based recommendations and thank you for your time today, Dr. Davis. Dr. Mellar Davis: Thank you. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/supportive-care-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

When Good Morning America's executive producer saw her doctor for joint pain, she never expected to be diagnosed with psoriatic arthritis—or that the medication prescribed to help her would trigger a life-threatening drug reaction. In Part 1 of this two-part episode, she shares her harrowing medical journey, from missed warning signs and delayed diagnosis to a year-long battle with the powerful steroid prednisone. We break down DRESS Syndrome, why medications are often overlooked as the cause of new symptoms, and the serious risks of steroids. Stay tuned for Part 2, where we explore how Cat's personal health crisis now shapes the national health news she brings to audiences on GMA3. Key Takeaways Don't ignore persistent symptoms. If you have fever, vomiting, or other concerning signs for more than 2 days, get medical care. Medications should always be on the suspect list. Adverse drug reactions don't always show up as a rash. They are great imitators of disease and may involve any organ system and without a rash. Oral steroids are powerful, but risky. They should never be the automatic go-to. If your doctor prescribes steroids, ask about alternatives and make sure there's a clear plan to taper off. Links GMA3: https://www.goodmorningamerica.com/author/gma3 Connect with Archelle ArcHealth Newsletter: https://www.archellemd.com/newsletter Email: SpeakUpForYourHealth@gmail.com Instagram:  https://instagram.com/speakupforyourhealth Facebook: https://www.facebook.com/speakupforyourhealth #arthritis #jointpain #sulfadrugs #drugallergy #GoodMorningAmerica #patientcare #patientadvocacy #prednisone

REV. TETTEH DJANGMAH IS THE SENIOR PASTOR OF TRUE VINE CHARISMATIC CHURCH INT.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Clonal Hematopoiesis Is Associated With Adverse Clinical Outcomes and Left Ventricular Remodeling in Aortic Stenosis

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Time Trends in Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention: Meta-Analysis on Sex Differences

David Liew talks to Claire Larter, a medical officer at the pharmacovigilance branch of the TGA, about her paper on adverse event reporting. Claire explains why pharmacovigilance is important for clinicians, and outlines what type of adverse events should be reported. The conversation also covers the process of reporting adverse events and how the TGA handles reports. Read the full article by Claire and her co-authors in Australian Prescriber.

Editor's Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief, and Preeti Malani, MD, MSJ, Deputy Editor of JAMA, the Journal of the American Medical Association, for articles published from February 1-7, 2025.

What are psychedelics? How do they impact your brain? Are they safe? Parker and Emma unpack the current research and legality of psychedelics and discuss the ethical implications of psychoactive drugs. Sources: Cheung, K., Earp, B. D., Patch, K., & Yaden, D. B. (2025). Distinctive But Not Exceptional: The Risks of Psychedelic Ethical Exceptionalism. The American Journal of Bioethics, 25(1), 16–28. Tiwari, P., Davoudian, P. A., Kapri, D., Vuruputuri, R. M., Karaba, L. A., Sharma, M., … Vaidya, V. A. (2024). Ventral hippocampal parvalbumin interneurons gate the acute anxiolytic action of the serotonergic psychedelic DOI. Neuron, 112(22), 3697-3714. Wang, E., Mathai, D. S., Gukasyan, N., Nayak, S., & Garcia-Romeu, A. (2024). Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. Healthcare Professionals. Scientific Reports, 14(1), 28022. Davis, A. K., Bates, M., Lund, E. M., Sepeda, N. D., Levin, A. W., Armstrong, S. B., … Yehuda, R. (2024). The Epidemiology of Psychedelic Use Among United States Military Veterans. Journal of Psychoactive Drugs, 1–14. Published Online. September 12, 2024. Ehrenkranz, R., Agrawal, M., Nayak, S. M., & Yaden, D. B. (2024). Adverse events should not be surprising in psychedelic research. Psychedelic Medicine. Published Online. September 4, 2024. Hinkle, J. T., Graziosi, M., Nayak, S. M., & Yaden, D. B. (2024). Adverse events in studies of classic psychedelics. JAMA Psychiatry, 81(12), 1225-1235. Yaden, D. B., Goldy, S. P., Weiss, B., & Griffiths, R. R. (2024). Clinically relevant acute subjective effects of psychedelics beyond mystical experience. Nature Reviews Psychology, 3(9), 606–621. Goldy, S. P., Hendricks, P. S., Keltner, D., & Yaden, D. B. (2024). Considering distinct positive emotions in psychedelic science. International Review of Psychiatry, 1–12. Published Online. September 2, 2024. Heller, N. H. & Barrett, F. S. (2024). Teaching a new dog old tricks: bringing rigor, grounding, and specificity to psychedelic neuropsychopharmacology. Neuropsychopharmacology. Published Online. August 26, 2024. Yaden, D. B., Mathai, D., Bogenschutz, M., & Nichols, D. E. (2024). The pharmacology of hallucinogens. In: Miller et al. (Eds.). Principles of Addiction Medicine. American Society of Addiction Medicine. Yaden, D. B., Nayak, S. M., Griffiths, R. R. (2024). Belief change and agnostic frames in psychedelic research and clinical contexts. In: C. Letheby (Ed.). Philosophy and the psychedelic renaissance. Oxford University Press, New York. DiRenzo, D., Barrett, F. S., Perin, J., Darrah, E., Christopher-Stine, L., & Griffiths, R. R. (2024). Impact of psilocybin on peripheral cytokine production. Psychedelic Medicine, 2(2). Cheung, K., Propes, C., Jacobs, E., Earp, B. D., & Yaden, D. B. (2024). Psychedelic group-based integration: Ethical assessment and initial recommendations. International Review of Psychiatry, 1–11. Tiwari, P., Ehrenkranz, R., & Yaden, D. B. (2024). Psychiatric Applications of Psychedelics: Neurobiological Foundations for Treatments of Depression, Anxiety, and Obsessive-Compulsive Disorder. Advances in Psychiatry and Behavioral Health. McGuire, A. L., Cohen, I. G., Sisti, D., Baggott, M., Celidwen, Y., Devenot, N., Gracias, S., Grob, C., Harvey, I., Kious, B., Marks, M., Mithoefer, M., Nielson, E., Öngür, D., Pallas, A., Peterson, A., Schenberg, E. E., Summergrad, P., Waters, B., Williams, M. T., & Yaden, D. B. (2024). Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement. JAMA Network Open, 7(6), e2414650.

The gang reunites after the battle with the Dragon Turtle cub and prepares for their treacherous journey. Adverse weather and new threats await them on the path to Twin Visages.

reference: Sri Aurobindo and the Mother, Powers Within, Chapter XX The Psychic, pp. 154-155 This episode is also available as a blog post at https://sriaurobindostudies.wordpress.com/2025/01/21/understanding-adverse-forces-and-the-evolutionary-response-to-their-action/ Video presentations, interviews and podcast episodes are all available on the YouTube Channel https://www.youtube.com/@santoshkrinsky871 More information about Sri Aurobindo can be found at www.aurobindo.net  The US editions and links to e-book editions of Sri Aurobindo's writings can be found at Lotus Press www.lotuspress.com

This episode is brought to you by Pique Life and Birch Living.  We used to think that the circadian rhythm only affected sleep. However, emerging science shows it's deeply connected to metabolism, cognition, chronic disease risk, and many other critical aspects of health. Our biology is designed to function in harmony with the natural light-dark cycle, but modern society has significantly disrupted this balance. Today on The Dhru Purohit Show, we bring you a special compilation episode featuring Dhru's conversations with leading experts on the critical role circadian rhythms play in our health and well-being. Dr. Satchin Panda delves into his groundbreaking research on circadian biology, revealing how leveraging your circadian rhythm can significantly improve sleep, reduce the risk of chronic diseases, and enhance cognitive function. He also shares how time-restricted eating, exercise, and light exposure can help program your circadian rhythm, with a special focus on the importance of these tools for shift workers. Dr. Moore-Ede discusses the dangers of chronic blue light exposure and its profound impact on health, highlighting research that reveals how it disrupts circadian rhythms. He also examines the connection between light exposure and obesity and explains why these risks remain underrepresented in mainstream media. Dr. Satchin Panda, a professor at the Salk Institute and founder of the UC San Diego Center for Circadian Biology, is a leading researcher in circadian biology. Dr. Martin Moore-Ede, a former Harvard Medical School professor and expert in circadian rhythms, has conducted groundbreaking research on light's role in regulating sleep-wake cycles and overall health. In this episode, Dhru and his guests dive into: Why when we eat is more important than what we eat (01:38) Effects of chronic late-night eating (08:18) Adverse effect of disrupting our circadian rhythm (16:25) What is sleep debt (19:21) Paying attention to when you eat (30:16) Research on time-restricted eating (34:08) Why sleeping with the lights on is damaging to your health (39:01) Why sun exposure is critical for good health (41:55) Dr. Martin's recommended time for sun exposure (49:28) The link between blue light and obesity (51:42) Master clock of the circadian rhythm, cortisol, melatonin, and others (54:06) Why doctors aren't talking about the harmful effects of blue lights (59:03) Blue lights in hospitals and how they prevent healing (01:04:47) Also mentioned: Full episode with Dr. Satchin Panda Full episode with Dr. Martin Ede-Moore This episode is brought to you by Pique Life and Birch Living.  Right now, Pique Life is offering 15% off the Radiant Skin Duo plus a free beaker and frother when you go to piquelife.com/dhru. To get 25% off your Birch Living mattress plus two free eco-rest pillows, head over to birchliving.com/dhru today. Learn more about your ad choices. Visit megaphone.fm/adchoices

Adverse Actions Lists for Certified Nurse Aides and Direct Service Workers: Performance Audit Services Senior Manager Emily Dixon recaps a new LLA report that evaluates the Louisiana Department of Health's oversight of its adverse actions lists for Certified Nurse Aides and Direct Service Workers with findings of abuse and neglect. | https://LLA.La.gov/go/podcast

Adverse Actions Lists for Certified Nurse Aides and Direct Service Workers: Performance Audit Services Senior Manager Emily Dixon recaps a new LLA report that evaluates the Louisiana Department of Health's oversight of its adverse actions lists for Certified Nurse Aides and Direct Service Workers with findings of abuse and neglect. | https://LLA.La.gov/go/podcast

Ethics in pharmacy is not just about following the law. It involves prioritizing our patients and understanding the ethical principles that pharmacists must follow. This podcast delves into a wide range of topics designed to provide complimentary continuing education programming to honor the ethical principle of beneficence and equip pharmacists, pharmacy technicians, and student pharmacists with resources, skills, and knowledge to handle ethical dilemmas in your practice to improve patient safety. This accredited podcast episode is worth 0.5 hours of Continuing Education Credit for Pharmacists and Pharmacy Technicians. So, whether you're a seasoned pharmacist looking to refresh your ethical knowledge or a new practitioner eager to build a solid ethical foundation, PEERx to PEER Pharmacy Talk is here for you.  

Singh v. Garland, No. 23-2065 (9th Cir. Dec. 24, 2024)prior adverse credibility & motion to reopen; disregarding affidavits; corroborating evidence; falsus in uno, falsus in omnibus; Mann party; Sikh; Badal Party Chmukh v. Garland, No. 21-1096 (9th Cir. Dec. 23, 2024)RCW § 69.50.4013; possession of stolen property aggravated felony; INA § 101(a)(43)(G); particularly serious crime; aggravated felony satisfying N-A-M- first step; dangerousness; issue exhaustion; Ukraine Magana-Magana v. Garland, No. 23-1887 (9th Cir. Dec. 26, 2024)VAWA motion to reopen; jurisdiction; mixed question of law and fact; extraordinary circumstances or extreme hardship to children; exhaustion; sua sponte Rodrigues v. Garland, No. 23-1776 (1st Cir. Dec. 27, 2024)well-founded fear; objective reasonableness; drug dealers in Brazil; political opinion opposition to powerful family Chacon-Ruiz v. Garland, No. 21-3694 (8th Cir. Dec. 24, 2024)motion to reopen for exceptional and extremely unusual hardship; motion to reconsider; children in foster care Mateo-Mateo v. Garland, No. 23-2694 (7th Cir. Dec. 24, 2024)family-related violence-type asylum; harm by family member Moctezuma-Reyes v. Garland, No. 24-0274 (6th Cir. Dec. 23, 2024)legal definition of exceptional and extremely unusual hardship; agency deference post-Loper Bright; star decisis post-Loper Bright; rare hardshipNational Immigration Project links:Trial Skills for Immigration CourtJ.O.P. v. DHS Settlement Agreement Sponsors and friends of the podcast!Kurzban Kurzban Tetzeli and Pratt P.A.Immigration, serious injury, and business lawyers serving clients in Florida, California, and all over the world for over 40 years.Docketwise"Modern immigration software & case management"Cerenade"Leader in providing smart, secure, and intuitive cloud-based solutions"Click me!Stafi"Remote staffing solutions for businesses of all sizes"Promo Code: stafi2024Get Started! Promo Code: FREECONTACT INFORMATIONEmail: kgregg@kktplaw.comFacebook: @immigrationreviewInstagram: @immigrationreviewTwitter: @immreviewAbout your hostCase notesRecent criminal-immigration article (p.18)Featured in San Diego VoyagerDISCLAIMER & CREDITSSee Eps. 1-200Support the show

Case round up:United States v. Burwell, No. 16-3009 (D.C. Cir. Dec. 9, 2024) – crime of violence; divisibility; Federal bank robbery in violation of U.S.C. § 2113(a); common law robbery; Mathis peek; jury instructionsTreez, Inc. v. DHS, Case No. 22-cv-07027 (N.D. Cal. Dec. 3, 2024) – marijuana dispensary; H-1B; aiding and abetting controlled substance act violation Bouarfa v. Mayorkas, et al., No. 23-583 (U.S. Dec. 10, 2024)revocation of I-130 petition; INA § 204(c); jurisdiction; discretion; may; INA § 242(a)(2)(B)(ii) Matter of Dominguez Reyes, 28 I&N Dec. 878 (BIA 2024)amount of loss; circumstance specific approach; INA § 101(a)(43)(D); certification of criminal documents  Quito-Guachichulca v. Garland, No. 23-1069 (8th Cir. Dec. 9, 2024)aggravated felony rape; INA § 101(a)(43)(A); sexual abuse; digital penetration; statutory interpretation; survey of state case law; res judicataMondzali Bopaka v. Garland, No. 21-1384 (1st Cir. Dec. 13, 2024)adverse credibility; motion to reopen to submit new evidence; I-589 errors and omissions; inconsistencies; ineffective assistance of counsel motion to reopen; Republic of the Congo Lopez-Quinteros v. Garland, No. 23-1890 (1st Cir. Dec. 13, 2024)family based particular social group; business owners; mixed motive; gang extortion; El SalvadorSponsors and friends of the podcast!Kurzban Kurzban Tetzeli and Pratt P.A.Immigration, serious injury, and business lawyers serving clients in Florida, California, and all over the world for over 40 years.Docketwise"Modern immigration software & case management"Cerenade"Leader in providing smart, secure, and intuitive cloud-based solutions"Click me!Stafi"Remote staffing solutions for businesses of all sizes"Promo Code: stafi2024Get Started! Promo Code: FREEImmigration Lawyer's Toolboxhttps://immigrationlawyerstoolbox.com/immigration-reviewWant to become a patron?Click here to check out our Patreon Page!CONTACT INFORMATIONEmail: kgregg@kktplaw.comFacebook: @immigrationreviewInstagram: @immigrationreviewTwitter: @immreviewAbout your hostCase notesRecent criminal-immigration article (p.18)Featured in San Diego VoyagerDISCLAIMER & CREDITSSee Eps. 1-200Support the show

Join us for this episode with Claudia Von Boeselager, the founder and CEO of Longevity & Lifestyle, to explore her mission around health optimization and longevity. She shares her journey into the world of longevity science and how she's personally worked to slow her own aging process. She offers valuable insights into cutting-edge strategies for supporting the gut-brain connection and preventing cognitive decline. Claudia also discusses groundbreaking research on ovarian aging, shedding light on the latest findings and their implications for women's health. Throughout the conversation, she emphasizes the importance of holistic approaches to health, combining science-backed strategies with lifestyle changes that support long-term vitality. Whether you're looking to optimize your overall health, protect your cognitive function, or simply slow the aging process, this episode is packed with actionable insights and expert advice. Tune in for a comprehensive look at the future of aging and longevity with one of the leading voices in the field.Claudia Von Boeselager is the Founder & CEO of Longevity & Lifestyle, a coaching and consulting platform that empowers leaders to optimize their life, health, and business, a Biohacker, International Keynote Speaker, and Host of The Longevity & Lifestyle Podcast. Over a decade of research and training have allowed Claudia to unlock the key strategies for health optimization and successfully biohack her age to 16 years younger than her chronological one. Claudia is a Peak Performance Coach with expertise in Breathwork, Mindset, NLP, Mindfulness, and Reiki Mastery. She is a serial entrepreneur, investor, former Investment Banker (Goldman Sachs), a mother of two, and adores sports, adventure, dancing, and Mexican food.SHOW NOTES:0:51 Welcome to the show!3:10 Claudia's Bio4:01 Welcome her to the podcast!4:37 How she got into health optimization7:42 Her mission around longevity8:30 Advice she would give to her corporate self10:45 How she slowed her pace of aging!14:12 Her gut repair protocol17:28 Avoiding cognitive decline & neurodegenerative diseases20:27 How gut health impacts brain health22:25 *SIPHOX HEALTH LABS*24:21 *CAROL BIKE*26:13 *MAGNESIUM BREAKTHROUGH*27:54 Extending ovarian aging29:13 Adverse pharmaceutical outcomes in women30:26 Can we extended the timeline for fertility?32:38 Neuro-Linguistic Programming (NLP)34:06 Biohacking vs Longevity defined36:29 What she's most excited about in women's health37:16 Brain-Heart Cohesion & Brain-Heart Variability38:46 Her final piece of advice39:33 Where to find her40:12 Thanks for tuning in!RESOURCES:Website: Longevity-and-LifestylePodcast: Longevity-and-LifestyleIG: longevityandlifestylePlaybook: 10 Biohacks to Increase Your LongevityPART 1 OF THIS INTERVIEW: Top Biohacking Strategies for Better Sleep, Longevity & RecoverySiphox Health Labs - Discount code: BIOHACKERBABESCAROL Bike - Discount code: BIOHACKERBABES for $250 offBiOptimizers Magnesium Breakthrough - Discount code for 10% off: biohackerbabes10Support this podcast at — https://redcircle.com/biohacker-babes-podcast/donationsAdvertising Inquiries: https://redcircle.com/brands

Ever wondered how the big players in financial services got to where they are? Matt and Micah dive deep into the secret behind Edward Jones' remarkable success story – and why independent advisors should be taking notes instead of throwing shade. They challenge the common "David vs. Goliath" mindset that often leads independent advisors to dismiss larger firms' achievements and reveal how Edward Jones' strategic playbook can be adapted for independent practice success. Listen in as they explore the often-overlooked truth about building a thriving advisory practice: it's not just about working harder but working smarter with intentionality. Compliance ‘Adverse' [Episode 285] Resources in today's episode: - Micah Shilanski: Website | LinkedIn - Matt Jarvis: Website | LinkedIn